Form 483

Zhejiang Jingxin Pharmaceutical Co., Ltd Form 483, 2025-10-17

FDA issued a Form 483 to Zhejiang Jingxin Pharmaceutical Co., Ltd on 2025-10-17 with 2 public-safe observations.

483· Form 483 issuedHuman Drugs2 observations

Zhejiang Jingxin Pharmaceutical Co., Ltd · Shaoxing, China · Issued October 17, 2025

Overview

  • 2 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

17 Oct 2025
21 CFR 211.165(b)

Microbiological testing

Cited by Carolina D Vasquez

17 Oct 2025
21 CFR 211.84(d)(1)

Identity Testing of Each Component

Cited by Carolina D Vasquez

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.165(b)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(1)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 2 observations

The full inspection record, as Atlas holds it, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere

Related Form 483s